Pictet Asset Management
DNTH icon

Pictet Asset Management’s Dianthus Therapeutics DNTH Stock Holding History

Pictet Asset Management’s Portfolio DNTH Stock Details DNTH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$24.1M Buy
247,295
+242,371
+4,922% +$21.2M 0.02% 493
2026
Q1 		$413K Buy
+4,924
New +$285K ﹤0.01% 1572

Other funds holding DNTH

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
EA
Emerald Advisers Leola, Pennsylvania $4.25B AUM 141.71% 1-Year Est. Return
TD Asset Management
TD Asset Management Toronto, Ontario, Canada $115B AUM 41.58% 1-Year Est. Return
TCM
TimesSquare Capital Management New York $6.8B AUM 45.85% 1-Year Est. Return
Russell Investments Group
Russell Investments Group London, United Kingdom $114B AUM 41.71% 1-Year Est. Return
EHI
Eagle Health Investments Greenwich, Connecticut $603M AUM 111.06% 1-Year Est. Return

Pictet Asset Management's DNTH Position: Q2 2026 in Review

Pictet Asset Management increased its Dianthus Therapeutics (DNTH) stake by 4,922% in Q2 2026, buying an estimated $21.2M and bringing the position to 247,295 shares worth $24.1M. The position accounts for 0.02% of the portfolio, ranked #493.

Pictet Asset Management first reported a position in DNTH in Q1 2026 and has held it in 2 quarters since. 84 funds tracked by Wall St. Rank hold DNTH as of Q2 2026.

  • Pictet Asset Management held 247,295 shares of Dianthus Therapeutics worth $24.1M as of Q2 2026.
  • Pictet Asset Management bought 242,371 Dianthus Therapeutics shares in Q2 2026, an estimated $21.2M.
  • Dianthus Therapeutics made up 0.02% of Pictet Asset Management's portfolio in Q2 2026, its #493 holding.
  • Pictet Asset Management first reported a position in Dianthus Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • 84 funds tracked by Wall St. Rank held Dianthus Therapeutics as of Q2 2026.

Based on Pictet Asset Management's 13F filing for Q2 2026, filed 30 Jul 2026.